The drug in plain words
What Is Semaglutide? It Copies 1 Gut Hormone
Start with the study results. Then see what the drug does, how long it lasts, and which uses the FDA allows.
What did Semaglutide change in the trials?
Large trials found lower weight and fewer major heart problems in the groups tested [1][3][6]. Kidney loss also slowed. That's the useful part. It tells you what changed, not what will happen to you.
This prescription drug copies glucagon-like peptide-1, a gut hormone often shortened to GLP-1. Your gut makes the hormone after food. Semaglutide lowers blood sugar and eases hunger. The FDA allows it for type 2 diabetes, long-term weight control, some heart risks, and MASH. MASH is a serious fatty-liver illness.
Peptides are small strings of protein parts. Semaglutide is one. One form is injected weekly; the tablet is taken daily. This page isn't personal medical advice or a sales offer.
How is the Semaglutide peptide built?
The Semaglutide peptide is a 31-amino-acid chain, made from small protein building blocks. About 94% of those blocks sit in the same order as the natural GLP-1 gut hormone. Its full name is glucagon-like peptide-1. A fatty chain helps the drug stick to the blood protein albumin. That slows the body's work of clearing it.
Two other changes help it last. Building blocks at spots 8 and 34 differ from the natural hormone. The first change makes it harder for DPP-4, the body's quick breakdown protein, to cut up the drug. Chemists put its weight at about 4,114 daltons. A dalton is a unit for the weight of a tiny molecule; that figure can't tell you whether the drug will help you.
The useful point is plain: a hormone that lasts two minutes became a weekly drug. How does semaglutide work explains what happens next.
What kind of drug is it?
Semaglutide belongs to a group of drugs that copy GLP-1, a gut hormone. The drugs turn on the same cell switch as that hormone. After food, the message brings out more insulin and curbs hunger.
Semaglutide stands out because it lasts a long time and comes as both a shot and pill. Its studies cover body weight plus the heart, kidneys, and liver. Tirzepatide is related but also copies a second message alongside GLP-1.
You can see the direct drug comparison on the Semaglutide research page.
Which uses has the FDA approved?
Semaglutide is an approved prescription medicine, not an experimental compound. The FDA has cleared it across several indications: type 2 diabetes, chronic weight management, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, in 2025, metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty-liver disease [9].
When Semaglutide enters an access discussion, the relevant category is clinician-reviewed access through licensed telehealth; Promise Peptides (mypromise.com) is one provider in that category, while this independent digest remains focused on the public record.
It is available in two formulations — a once-weekly subcutaneous injection and a once-daily oral tablet. The evidence behind these indications comes from large randomized trials: STEP for weight management [1], SUSTAIN-6 and SELECT for cardiovascular outcomes [2][3], FLOW for kidney outcomes [6], and ESSENCE for liver disease [8]. Each is summarized on the research page and listed on the references page.
What are the main gains and drawbacks?
Doctors use Semaglutide to lower blood sugar in type 2 diabetes and aid long-term weight control. Trials also counted fewer kidney and heart problems in certain groups. Many users say hunger and cravings fell. Their accounts appear on Semaglutide effects, apart from trial findings.
The main trade is stomach trouble. Nausea, vomiting, diarrhea, and hard stools were common, mainly as the amount rose [5]. The label puts a rare thyroid tumor seen in rats in its strongest warning box [16]. Studies also found more gallbladder trouble [5]. Stopping the drug was followed by a large weight regain [13].
Those drawbacks aren't fine print. Keep them beside the gains.
How did the approved uses grow?
2017 brought the first FDA approval for type 2 diabetes [1]. The pill followed in 2019-2020. Approval for long-term weight control came in 2021.
In 2023, SELECT reported its heart results [3]. In 2024, FLOW gave its kidney results [6]. A MASH use followed in 2025 [8].
Federal shortage rules applied from about 2022 to early 2025. They let compounding pharmacies make Semaglutide. That route narrowed when the shortage ended [9]. A compounded drug isn't the same under the law as the approved product used in the main trials.
That's a reading of the public record, not legal advice.